The technological core of this shift lies in the ability to measure behavior and neural activity with unprecedented temporal, chemical, and spatial resolution. Genetically encoded biosensors can now report the release of neuropeptides such as opioids in living tissue, a capability highlighted in a 2024 Nature Neuroscience study that the editorial cites as emblematic of the new toolkit. Fiber photometry systems, paired with open-source analysis software such as the Python library Pyfiber, allow researchers to integrate operant behavior with real-time fluorescence signals, linking moment-to-moment neural dynamics to the choices animals make. Optogenetic approaches have matured to the point where researchers can mimic aspects of drug action in defined circuits, dissecting the dopamine-dependent core of addiction with cell-type specificity. Automated behavioral tracking and computational analyses complete the picture, replacing coarse endpoints such as total drug consumed with rich, continuous streams of data that capture how brain activity and behavior shape one another over time.

That temporal dimension matters because, as the editors emphasize, addiction is not a static state. It is a dynamic sequence of processes, including drug use, seeking, withdrawal, craving, and relapse, each shaped by internal states and external cues and expressed in environments full of competing rewards. Conventional experimental designs, which typically sample behavior at isolated time points, can miss exactly the transitions that matter most clinically: the moment a cue triggers craving, the slow emergence of social withdrawal during abstinence, or the drift from controlled use to compulsive consumption. Continuous monitoring and increasingly sophisticated behavioral models offer a way to capture those processes. Within the Research Topic, Mathis and colleagues introduce a novel, automated, and unbiased approach to characterizing the emergence of social deficits during morphine abstinence in mice. By providing long-term longitudinal and quantitative assessment of social behavior, the work reveals dimensions of withdrawal that conventional assays simply do not register, illustrating how better phenotyping can expose previously invisible features of the addicted state.

Human studies in the collection follow the same logic of dynamic, quantified measurement. Yilmazer and colleagues investigate whether new neurophysiological biomarkers can track gambling disorder, focusing specifically on theta cordance, an electroencephalographic measure. Their approach exemplifies how analytical methods such as Granger Causality, which tests whether activity in one brain region predictively influences activity in another, can be leveraged to move diagnosis beyond self-report and toward objective, physiology-based indicators. The editors suggest that such biomarkers could eventually improve diagnosis and guide the implementation of treatment, a prospect that resonates far beyond gambling. If neural signatures can index the severity and trajectory of a behavioral addiction, the same logic may apply across the spectrum of substance use disorders, where clinicians currently lack reliable tools for predicting who will relapse and when.

Yet the editors are careful to temper enthusiasm with a caution: methodological innovation and basic discovery alone will not revolutionize clinical practice. More detailed behavioral phenotyping does not automatically yield mechanistic understanding, and identifying patterns of neural circuit activity that correlate with addictive states does not reveal the core cognitive disruptions that seed maladaptive behavior. The central challenge, they argue, is determining which measurements meaningfully explain the emergence and persistence of maladaptive behaviors, and translating that understanding into new diagnostic and prognostic tools. Correlation is not explanation, and a flood of high-resolution data is only as valuable as the questions it is used to answer. This framing sets the intellectual agenda for the rest of the collection, which repeatedly asks not just what the brain is doing during addiction, but which of those measurements actually matter.

Several contributions point toward a redefinition of addiction itself, shifting from substance-centered categories to shared mechanisms. Insalaco and colleagues examined longitudinal changes in physiological and mental-health functioning among individuals receiving treatment for substance use disorders, underscoring the importance of tracking addiction-related outcomes over time. Their findings offer insight into the dynamics of substance use disorder as a clinical condition and could be used to tailor therapeutic interventions at different points in its trajectory, rather than applying the same strategy regardless of stage. Allache and colleagues go further, proposing craving as a potential transdiagnostic marker for both substance and behavioral addictions. The implication is provocative: instead of defining addiction by the substance or behavior involved, clinicians and researchers might orient diagnosis around core mechanisms shared across different forms of pathological behavior, unifying disorders that the current diagnostic framework keeps separate.

The reach of addiction biology may extend even beyond the brain. Tyrode and colleagues suggest that gut microbiota signatures could be predictive of both cocaine use and binge eating disorder, a viewpoint that pushes addiction research into peripheral biological systems and reinforces the idea that seemingly distinct disorders may share biological fingerprints. The gut-brain axis has become one of the most active frontiers in neuroscience, and its appearance in addiction research signals how far the field has traveled from a purely dopaminergic account of reward. Alongside this, a review by O’Connor revisits the controversial concept of food addiction in the context of GLP-1-based obesity pharmacotherapy, the class of drugs that has transformed treatment of metabolic disease. By examining the overlap between neural pathways regulating feeding and those implicated in substance use, the review illustrates both the value and the limitations of identifying shared reward mechanisms across disorders. Crucially, it also demonstrates how societal motives must be considered in the evolution of the addiction concept, a reminder that scientific categories are shaped as much by culture as by data.

What emerges from the collection as a whole is a convergence, despite contributions spanning animal and human research, experimental and clinical investigations, and multiple subtypes of addiction-like behavior, on a single message: understanding addiction requires studying the dynamic interactions between biological mechanisms, behavior, and context. The editors highlight three complementary shifts now reshaping the field, moving from static measures to dynamic trajectories, from isolated brain circuits to interacting biological systems, and from substance-centered definitions to mechanistically informed models of maladaptive behavior. They also stress nuance: food and drugs engage overlapping motivational systems, but feeding is embedded within metabolic regulation and physiological homeostasis, so problematic eating necessarily manifests with both overlapping and unique underpinnings relative to psychoactive drugs. Not every reward-based behavior leads to addiction, and true progress will require acknowledging the complex interplay of environmental, cognitive, neurochemical, and genetic predispositions that seed addiction in certain individuals rather than in others.

The editorial closes with a formulation that may define the next decade of the field. The future of addiction research, the authors write, will not be defined solely by the ability to measure more molecules, record more neurons, or quantify more behavioral dimensions; progress will depend on using those technologies to ask better questions and to improve analysis and interpretation. Rethinking addiction, they suggest, does not necessarily mean expanding its definition. It may instead mean refining it: identifying when, why, and for whom a behavior becomes persistent, maladaptive, and difficult to control. That conceptual refinement, supported by increasingly sophisticated technologies and integrative approaches spanning brain, body, and environment, may ultimately provide a stronger foundation for more precise diagnosis, prevention, and treatment, turning a period of methodological exuberance into a period of genuine clinical advance.

Subject of Research: Technological and conceptual advances in addiction neuroscience and the re-evaluation of substance use disorders

Article Title: Editorial: Rethinking addiction: technological advances, mechanistic insights, and the re-evaluation of substance use disorders

Article References: Darcq, E., Howe, W. M., Nicolas, C., & Mathis, V. P. (2026). Editorial: Rethinking addiction: technological advances, mechanistic insights, and the re-evaluation of substance use disorders. Frontiers in Behavioral Neuroscience, 20, Article 2009605. https://doi.org/10.3389/fnbeh.2026.2009605

Image Credits: AI Generated

DOI: 10.3389/fnbeh.2026.2009605

Keywords: addiction, substance use disorders, behavioral neuroscience, biosensors, craving, gambling disorder, gut microbiota, food addiction, GLP-1, neural circuits, biomarkers, relapse

The trial’s central hypothesis is deceptively simple but clinically consequential: the depressive and other affective symptoms that emerge during medication-assisted treatment or periods of reduced opioid use may act as motivational triggers for relapse. If ketamine can rapidly lift those symptoms, it might close a therapeutic window that current medications leave open. Ketamine has already demonstrated striking promise as a rapid-acting intervention in mood disorders, but its efficacy, safety and neuro-bio-physiological effects in people with opioid use disorder remain insufficiently characterised. This study is designed to fill that evidence gap with clinical, mechanistic and safety data.

The design is a classic test of adjunctive therapy. Participants with opioid use disorder who are already receiving medications for opioid use disorder will be randomised to receive either six intravenous infusions of ketamine at 0.5 milligrams per kilogram of body weight or a placebo over a two-week period. Clinical outcomes will be assessed at baseline, throughout the infusion phase, in an acute primary analysis window extending through two weeks after the final infusion, and at follow-up time points stretching to nine months after the last infusion. That long tail of follow-up is unusual for ketamine studies and reflects the trial’s explicit focus on relapse prevention rather than short-term symptom relief alone.

A notable feature of the protocol is its disciplined endpoint hierarchy. In a substantial protocol modification submitted in July 2026, the investigators replaced a previously registered broad, composite primary objective with a single primary clinical endpoint: change in total score on the Montgomery-Åsberg Depression Rating Scale over the acute primary analysis window. Everything else, including longer-term depression follow-up, craving, withdrawal symptoms, treatment retention, lapse and relapse-related outcomes, safety, electroencephalography, heart rate variability and peripheral biomarkers, is retained as secondary or exploratory. The revision was adopted to avoid a composite primary endpoint mixing heterogeneous domains and to align the protocol with SPIRIT and ICH E9 principles for coherent analysis.

The measurement battery is unusually comprehensive for a psychiatry trial of this size. Depression will be tracked with the Montgomery-Åsberg scale and the Patient Health Questionnaire-9, anxiety with the Generalised Anxiety Disorder-7 and the state version of the State-Trait Anxiety Inventory, and overall psychological distress with the Depression Anxiety Stress Scales-21. Craving will be measured with the Brief Substance Craving Scale, while withdrawal is monitored through both the Subjective and Objective Opiate Withdrawal Scales. Emotion regulation, alexithymia, anhedonia and positive and negative affect are captured with dedicated instruments, including the Difficulties in Emotion Regulation Scale-18, the Toronto Alexithymia Scale-20, the Snaith-Hamilton Pleasure Scale, the Temporal Experience of Pleasure Scale and the Positive and Negative Affect Schedule. A primary care screen for post-traumatic stress disorder rounds out the affective picture.

Beyond the clinical scales, the study is built to probe mechanism. Electroencephalography will track changes in brain oscillatory activity, heart rate variability will index autonomic nervous system function, and blood-based biomarkers, including brain-derived neurotrophic factor and stress-axis hormones such as adrenocorticotropic hormone and corticotropin-releasing factor, will be sampled to map the hypothalamic-pituitary-adrenal axis response. Dissociative effects during infusions will be quantified with the six-item Clinician-Administered Dissociative States Scale, and recovery from each session will be verified with the Modified Aldrete Score. By weaving together clinical, neurophysiological, autonomic and molecular measures, the investigators aim to identify candidate mechanisms of action and potential predictors of ketamine response, information that could eventually allow clinicians to select which patients are most likely to benefit.

Safety receives equally careful attention. Adverse events will be graded with the Common Terminology Criteria for Adverse Events, tracked through an adverse event checklist, and monitored with electrocardiograms. The protocol specifies halting rules, blinding-integrity assessment and procedures for handling concomitant medications, all clarified in the revised version 2.0 dated 13 July 2026. The trial was approved by the Cyprus National Bioethics Committee on 28 April 2022, received regulatory authorisation in EudraCT on 17 November 2022 before the first participant was enrolled, and was subsequently assigned EU CT Number 2025-520843-34-00 following the transition to the Clinical Trials Information System. It is being conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines, with written informed consent from all participants.

The trial’s status is a study in methodological transparency. Recruitment began on 2 April 2024, after prospective registration. At the time of manuscript submission, fourteen participants had been enrolled and randomised, and all fourteen had received at least one ketamine or placebo infusion. Thirteen had completed the full six-infusion treatment phase and entered the post-treatment follow-up phase. No serious adverse events had occurred to date. Crucially, the investigators report only aggregate blinded status data; no treatment-arm-specific outcome data have been examined or disclosed while the study remains blinded, and investigators, treating clinicians, outcome assessors, laboratory personnel and data analysts all remain unaware of allocation.

The study is anchored at the University of Cyprus, with the Department of Psychology and the Center for Applied Neuroscience at its core, and involves the GEFYRA Substitute Substance Unit in Nicosia, the State Health Services Organization of Cyprus, the Athalassa Psychiatric Hospital Pharmacy, European University Cyprus, Umeå University in Sweden and a clinical laboratory in Larnaca. Funding comes from the Research and Innovation Foundation of Cyprus under grant numbers EXCELLENCE/0421/0543 and EXCELLENCE/0524/0357, with the funder having no role in study design, data collection, analysis, interpretation or publication decisions. The sponsor is the University of Cyprus, which carries responsibility for trial oversight, safety reporting and insurance arrangements in line with Regulation (EU) No 536/2014.

What makes this protocol newsworthy is its positioning within the broader ketamine story. Ketamine’s rapid antidepressant action, mediated through glutamatergic pathways and studied intensively in treatment-resistant depression, has never been rigorously tested as an adjunct in opioid use disorder at this level of mechanistic depth. If the PROUD study demonstrates meaningful reductions in depressive symptoms and downstream effects on craving and relapse, it would inform the design, sample-size assumptions and endpoint selection of larger multicentre trials targeting affective symptoms and relapse vulnerability in opioid use disorder, with relevance to concomitant multidisciplinary rehabilitation approaches. If it does not, the rich biomarker dataset should still clarify why, sharpening the field’s understanding of who responds and why. Either way, the trial’s transparent registration, disciplined endpoint hierarchy and nine-month follow-up set a methodological benchmark for adjunctive interventions in addiction medicine, a field where relapse, not abstinence at discharge, is the outcome that ultimately determines whether treatment saves lives.

Subject of Research: A randomised, double-blind, placebo-controlled phase II trial protocol testing adjunctive intravenous ketamine for affective symptoms, craving and relapse prevention in opioid use disorder

Article Title: Adjunctive ketamine for affective symptoms, craving, and relapse prevention in opioid use disorder: protocol for a randomised, double-blind, placebo-controlled clinical trial

Article References: Koumas, M., Apostolakis, M., Bella, E., Michael, A., Onisiforou, A., Georgiou, P., Papacharalambous, C., Kyprianides, P., Stylianou, M., Paraskevopoulos, E., Panayiotou, G., Fotopoulos, D., Chatzittofis, A., & Zanos, P. (2026). Adjunctive ketamine for affective symptoms, craving, and relapse prevention in opioid use disorder: protocol for a randomised, double-blind, placebo-controlled clinical trial. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08628-3

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08628-3

Keywords: ketamine, opioid use disorder, clinical trial, depression, relapse prevention, MOUD, psychiatry, biomarkers, EEG, craving, Adjunctive, affective

The concept at the heart of the study is called interpersonal brain synchronization, or IBS. When two people interact, whether cooperating on a task or competing against each other, their brain activity patterns can become correlated, rising and falling together in ways that reflect the quality of the social exchange. Researchers measure this using functional near-infrared spectroscopy, or fNIRS, a non-invasive optical technique that tracks changes in oxygenated and deoxygenated hemoglobin in the outer layers of the cortex. By recording two participants simultaneously and calculating the correlation between their hemodynamic signals in specific regions of interest, scientists can quantify how strongly two brains are coupling during a shared task. Previous work has linked atypical IBS to social interaction difficulties in several psychiatric conditions, and the team behind the new trial reasoned that gaming disorder, which is characterized by impaired social function and heightened gaming cravings in the International Classification of Diseases 11th Revision, might also involve disrupted interpersonal neural coupling.

To test whether that coupling could be changed, the researchers designed a randomized, double-blind, sham-controlled trial, registered at ClinicalTrials.gov as NCT06208358. They recruited 60 men with gaming disorder in Hunan, China, and randomly assigned them to an active HI-tACS group of 30 participants arranged in 15 dyads, or a sham group of 30 participants also arranged in 15 dyads. The active group received 10 sessions of HI-tACS over two weeks, while the sham group received a sham intervention designed to mimic the experience without delivering the same neural modulation. The use of dyads is central to the design: because IBS is a property of two interacting brains, the intervention had to be evaluated in pairs of participants performing social tasks together, rather than in isolated individuals. The trial was approved by the Institutional Review Board of the Shanghai Mental Health Center and carried out in accordance with the Declaration of Helsinki, with all subjects providing informed consent.

The stimulation itself deserves explanation. Transcranial alternating current stimulation applies a weak oscillating electrical current to the scalp, and when the frequency of that current matches a natural brain rhythm, it can entrain or amplify neural oscillations in the underlying cortex. Gamma-frequency stimulation targets the fast oscillations associated with cognitive control, attention, and social cognition. The high-intensity variant used in this trial delivers stronger currents than conventional tACS devices, with the aim of reaching deeper or more robustly modulating cortical circuits. The technique is distinct from transcranial direct current stimulation, which applies a steady current, and from repetitive transcranial magnetic stimulation, which uses magnetic pulses. By entraining gamma activity, the researchers hoped to influence the prefrontal and temporoparietal circuits that support social interaction and craving regulation in gaming disorder.

The primary outcomes were gaming cravings, measured with validated scales, and fNIRS-based IBS during structured competition and cooperation tasks performed by the dyads. The researchers analyzed the data using linear mixed models, a statistical framework well suited to repeated-measures designs in which participants are nested within dyads and measured before and after the intervention. The models tested for a Time by Group interaction, which would indicate that the active and sham groups changed differently over the course of the trial. The analysis followed an intention-to-treat approach, and the team controlled for multiple comparisons using false discovery rate procedures at the region-of-interest level, with additional single-channel analyses providing finer spatial resolution.

The craving results were suggestive but statistically delicate. Linear mixed models revealed a significant Time by Group interaction effect on gaming cravings, with an F statistic of 4.95 on 1 and 52.5 degrees of freedom and a p value of 0.03, indicating that the two groups’ craving trajectories diverged over the intervention period. However, the post-hoc comparisons did not reach statistical significance, meaning the researchers could not confirm precisely which group changed relative to which at the pairwise level. This pattern, a significant omnibus interaction without significant post-hoc tests, is common in trials of this size and suggests that the craving effect, while promising, requires replication in larger samples before any clinical claim can be made. The authors are careful to frame the findings as initial neurophysiological evidence rather than proof of therapeutic efficacy.

The interpersonal brain synchronization results were more spatially specific and, in some ways, more surprising. In the competition task, IBS showed significant Time by Group interaction effects at the single-channel level in two regions: the right temporoparietal junction, with F of 10.56 on 1 and 25 degrees of freedom and p equal to 0.04, and the left ventrolateral prefrontal cortex, with F of 11.50 on 1 and 21.6 degrees of freedom and p equal to 0.03. The direction of the effects was intriguing: after the intervention, IBS decreased in the active group and increased in the sham group. At first glance, a decrease in synchronization might seem undesirable, but the interpretation is subtler. Elevated between-brain coupling is not automatically a marker of healthy interaction; in some contexts, excessive synchronization may reflect rigid or hyper-coordinated neural dynamics. The reduction observed in the stimulated group may indicate a normalization of neural coupling toward more flexible patterns of social engagement.

Perhaps the most clinically resonant finding came from an exploratory correlation analysis. The researchers found that the reduction in IBS in the right temporoparietal junction was associated with participants’ increased perceived social support, as measured by the Perceived Social Support Scale. The right temporoparietal junction is a hub of the social brain, consistently implicated in theory of mind, the capacity to attribute mental states to others, and in perspective-taking during competitive and cooperative exchanges. If reduced synchronization in this region tracks with feeling more socially supported, it lends weight to the idea that the neural changes induced by HI-tACS are not merely artifacts of stimulation but relate meaningfully to participants’ lived social experience. This link between a laboratory neural measure and a real-world psychosocial construct is exactly the kind of bridge the field needs if brain-based interventions are to translate into functional recovery.

The trial is not without limitations, and the authors acknowledge them. The sample consisted exclusively of 60 men, which limits generalizability to women and to the broader population of people with gaming disorder. The craving result lacked significant post-hoc support, and the IBS findings emerged at the single-channel level in the competition task, warranting confirmation in independent cohorts. The two-week, ten-session protocol raises questions about the durability of any neural changes, and the study did not establish whether reduced IBS in competition predicts long-term reductions in gaming severity. Still, the randomized, double-blind, sham-controlled design, the preregistration, the dyadic fNIRS methodology, and the intention-to-treat analysis represent a methodological step forward for a field where many brain stimulation studies are small, unblinded, or exploratory.

The broader significance of the work lies in its reframing of what treatment for gaming disorder might look like. Cognitive behavioural therapy remains the most common psychological approach, but it does not directly target the neural circuits of social interaction, and pharmacological options are limited. If interpersonal brain synchronization is indeed a modifiable mechanism, brain stimulation could become a tool not just for reducing cravings but for restoring the social function that gaming disorder erodes. The Shanghai team’s findings offer the first randomized controlled evidence that gamma-frequency HI-tACS can shift between-brain coupling in the temporoparietal and prefrontal regions of people with gaming disorder, and that these shifts relate to how socially supported participants feel. Larger trials with longer follow-up, mixed-sex samples, and clinical outcome measures will determine whether this approach can move from an intriguing neurophysiological signal to a genuine therapeutic option. For now, the study opens a provocative possibility: that the social difficulties of gaming disorder are written in the synchrony between brains, and that synchrony can be retuned.

Subject of Research: High-intensity transcranial alternating current stimulation effects on interpersonal brain synchronization and gaming cravings in gaming disorder

Article Title: Effects and mechanism of High-Intensity transcranial Alternating Current Stimulation (HI-tACS) for social interaction and cravings in gaming disorder: a randomized controlled trial

Article References: Huang, C., Wang, Z., Zeng, Y., Shan, H., Lu, J., Chen, Y., Du, J., Jiang, H., Deng, M., Chen, T., Li, S., Su, H., Zhao, M., & Zhong, N. (2026). Effects and mechanism of High-Intensity transcranial Alternating Current Stimulation (HI-tACS) for social interaction and cravings in gaming disorder: a randomized controlled trial. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08576-y

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08576-y

Keywords: gaming disorder, HI-tACS, transcranial alternating current stimulation, interpersonal brain synchronization, fNIRS, temporoparietal junction, ventrolateral prefrontal cortex, craving, social interaction, randomized controlled trial, brain stimulation, social support

The scale of the problem motivating the study is considerable. New psychoactive substances—a shifting family of synthetic compounds designed to mimic the effects of controlled drugs while evading legal restrictions—have become one of the most difficult fronts in global drug policy. Because their chemical structures change constantly, their health consequences are poorly characterized, and people who begin using them in adolescence face heightened risks of lasting neurobiological and psychological harm. The adolescent brain, with its early-maturing reward circuitry and still-developing self-control systems, is particularly vulnerable to substance initiation and to the entrenched patterns of craving that follow.

To uncover the hidden structure of craving, the researchers assessed 1,008 patients in Tianjin whose substance use disorder began during adolescence. Rather than reducing craving to a single score, the team measured three separate dimensions: the intensity of craving itself, the degree to which it interfered with daily functioning, and the effort patients expended resisting it. Latent profile analysis—a form of statistical modeling that sorts individuals into unobserved subgroups based on patterns across multiple measures—was then applied to see whether distinct combinations of these dimensions existed within the sample.

Three profiles emerged, and they were strikingly uneven in size. The largest group, accounting for 54 percent of participants, was labeled relatively stable, showing moderate craving without overwhelming functional disruption. A second group, 40.2 percent of the sample, fell into a high craving struggle category marked by intense urges and an exhausting internal battle to resist them. The smallest but most concerning group, 6 percent, was described as functionally impaired, in which craving severely disrupted everyday life. That two in five patients occupied the high struggle profile underscores how common severe craving is in this population—and how misleading it would be to treat them all identically.

Identifying the profiles was only the first step. The team then asked whether psychosocial information could predict which profile a patient belonged to, using three machine learning models of increasing sophistication: logistic regression, a classical statistical baseline; random forest, an ensemble method that averages many decision trees; and XGBoost, a gradient-boosted algorithm known for its performance on tabular medical data. Performance was evaluated using macro-AUC, accuracy, and Macro-F1 scores, metrics that account for the imbalanced group sizes. XGBoost achieved the strongest discrimination among the three, although the researchers are candid that overall classification performance remained modest—a limitation they attribute to the exploratory nature of the work and the complexity of the underlying constructs.

Perhaps the most clinically valuable output came from interpreting the models. Using SHAP, an explainability technique that quantifies each feature’s contribution to predictions, the researchers identified the psychosocial variables that most strongly distinguished the craving subgroups. Social support emerged as a leading factor, consistent with a growing body of evidence that supportive networks buffer against relapse. Resistance to peer influence also ranked highly—a finding that resonates with developmental research showing adolescence as the period of peak susceptibility to peer pressure. Coping style, childhood adversity, age, and age at first drug use completed the list of key contributors, weaving together life history, developmental timing, and present-day resources into a single predictive picture.

These findings align closely with the biopsychosocial model of addiction, which holds that substance use disorders arise from interactions among biological vulnerability, psychological processes, and social context rather than from any single cause. The prominence of childhood adversity in the models echoes systematic reviews linking early maltreatment to elevated risk of substance misuse, while the role of social support reflects studies demonstrating that perceived support moderates the relationship between stress and relapse. By embedding these factors in a quantitative, subgroup-aware framework, the study gives that conceptual model a practical, data-driven form.

The authors are careful to frame the work as exploratory rather than definitive. The cross-sectional design captures a single moment in time and cannot establish causal direction—for instance, whether low social support drives intense craving or vice versa. The modest discriminative performance means the models are not yet ready for individual-level clinical decisions, and the data, which contain sensitive personal information, are not publicly available for reasons of privacy protection. Still, the researchers argue that the approach may provide preliminary evidence for risk stratification and for subgroup-sensitive addiction nursing support, in which care is tailored to whether a patient fits the stable, high struggle, or functionally impaired pattern.

If future longitudinal studies confirm and refine these profiles, the implications could be far-reaching. A patient in the functionally impaired group might warrant immediate intensive intervention, while someone in the high craving struggle group might benefit most from coping-skills training and peer-resistance support, and those in the stable group from relapse prevention and social strengthening. In an era when new psychoactive substances continually outpace regulation and traditional treatment models, the ability to sort patients by their actual craving signature—rather than a one-size-fits-all label—could mark a meaningful shift toward precision medicine in addiction care. The study, funded by the Ministry of Education in China, is an early but provocative demonstration that the algorithms of machine learning can find order in one of addiction’s most stubborn and subjective experiences.

Subject of Research: Exploratory risk stratification of adolescent-onset new psychoactive substance use disorder using latent craving profiles and machine learning

Article Title: Exploratory Risk Stratification of Patients With Adolescent-Onset New Psychoactive Substance Use Disorder: Integrating Latent Craving Profiles, Psychosocial Factors, and Machine Learning

Article References: Zhuang, S., Che, X., Song, Y., Li, S., Shang, X., Shi, L., Zhang, X., Song, C., Jing, J., Fan, J., Qin, S., Xu, Z., Zhang, J., Li, J., Li, L., Hou, K., & Jiang, Y. (2026). Exploratory Risk Stratification of Patients With Adolescent-Onset New Psychoactive Substance Use Disorder: Integrating Latent Craving Profiles, Psychosocial Factors, and Machine Learning. International Journal of Mental Health and Addiction. https://doi.org/10.1007/s11469-026-01714-3

Image Credits: AI Generated

DOI: 10.1007/s11469-026-01714-3

Keywords: new psychoactive substances, adolescent-onset substance use disorder, craving, latent profile analysis, machine learning, XGBoost, SHAP, social support, childhood adversity, risk stratification, addiction nursing, peer influence